» Articles » PMID: 24223915

Γ-secretase Components As Predictors of Breast Cancer Outcome

Overview
Journal PLoS One
Date 2013 Nov 14
PMID 24223915
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

γ-secretase is a large ubiquitously expressed protease complex composed of four core subunits: presenilin, Aph1, PEN-2, and nicastrin. The function of γ-secretase in the cells is to proteolytically cleave various proteins within their transmembrane domains. Presenilin and Aph1 occur as alternative variants belonging to mutually exclusive γ-secretase complexes and providing the complexes with heterogeneous biochemical and physiological properties. γ-secretase is proposed to have a role in the development and progression of cancer and γ-secretase inhibitors are intensively studied for their probable anti-tumor effects in various types of cancer models. Here, we for the first time determined mRNA expression levels of presenilin-1, presenilin-2, Aph1a, Aph1b, PEN-2, and nicastrin in a set of breast cancer tissue samples (N = 55) by quantitative real-time PCR in order to clarify the clinical significance of the expression of different γ-secretase complex components in breast cancer. We found a high positive correlation between the subunit expression levels implying a common regulation of transcription. Our univariate Kaplan-Meier survival analyses established low expression level of γ-secretase complex as a risk factor for breast cancer specific mortality. The tumors expressing low levels of γ-secretase complex were characterized by high histopathological tumor grade, low or no expression of estrogen and progesterone receptors and consequently high probability to fall into the class of triple negative breast cancer tumors. These results may provide novel tools to further categorize breast cancer tumors, especially the highly aggressive and poorly treatable breast cancer type of triple negative cases, and suggest a significant role for γ-secretase in breast cancer.

Citing Articles

The critical role of γ-secretase and its inhibitors in cancer and cancer therapeutics.

Song C, Zhang J, Xu C, Gao M, Li N, Geng Q Int J Biol Sci. 2023; 19(16):5089-5103.

PMID: 37928268 PMC: 10620818. DOI: 10.7150/ijbs.87334.


Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer.

Yousefi H, Bahramy A, Zafari N, Delavar M, Nguyen K, Haghi A BMC Cancer. 2022; 22(1):1282.

PMID: 36476410 PMC: 9730604. DOI: 10.1186/s12885-022-10383-z.


Role of Presenilin-1 in Aggressive Human Melanoma.

Sidor J, Gillette M, Dezi L, Untiveros G, Strizzi L Int J Mol Sci. 2022; 23(9).

PMID: 35563300 PMC: 9099829. DOI: 10.3390/ijms23094904.


Aberrations of Chromosomes 1 and 16 in Breast Cancer: A Framework for Cooperation of Transcriptionally Dysregulated Genes.

Privitera A, Barresi V, Condorelli D Cancers (Basel). 2021; 13(7).

PMID: 33808143 PMC: 8037453. DOI: 10.3390/cancers13071585.


Tomatidine Represses Invasion and Migration of Human Osteosarcoma U2OS and HOS Cells by Suppression of Presenilin 1 and c-Raf-MEK-ERK Pathway.

Hsieh M, Yang J, Lin R, Hsieh Y, Yang S, Chang H Molecules. 2020; 25(2).

PMID: 31941156 PMC: 7024336. DOI: 10.3390/molecules25020326.


References
1.
Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L . Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A. 1999; 96(21):11872-7. PMC: 18379. DOI: 10.1073/pnas.96.21.11872. View

2.
Lai M, Chen E, Crouthamel M, DiMuzio-Mower J, Xu M, Huang Q . Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities. J Biol Chem. 2003; 278(25):22475-81. DOI: 10.1074/jbc.M300974200. View

3.
Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

4.
Proweller A, Tu L, Lepore J, Cheng L, Lu M, Seykora J . Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 2006; 66(15):7438-44. DOI: 10.1158/0008-5472.CAN-06-0793. View

5.
Debeb B, Cohen E, Boley K, Freiter E, Li L, Robertson F . Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012; 134(2):495-510. PMC: 4545650. DOI: 10.1007/s10549-012-2075-8. View